Biolife solutions reports third quarter 2024 financial results

Cell processing revenue grew 6%  sequentially to $19.0 million; 43% increase compared to 2023 gaap gross margin of 51%  and non-gaap adjusted gross margin of 54% gaap net loss from continuing operations of $1.7 million and non-gaap adjusted ebitda of $6.1 million or 20% increasing cell processing revenue guidance by $2 million to $72.0 to $73.0 million; total 2024 revenue guidance of $98.0 million to $100.0 million reflecting impact of scisafe divestiture conference call begins at 4:30 p.m. eastern time today bothell, wash.
BLFS Ratings Summary
BLFS Quant Ranking